594784 Disclosed is the use of an anti-CD4 antibody or antigen binding fragment thereof in the manufacture of a medicament for the treatment of a CD4+ T-cell mediated condition selected from the group consisting of primary cancer, metastatic cancer and inflammatory skin disease in a subject, wherein the anti-CD4 antibody is selected from the group consisting of: (a) zanolimumab, keliximab, clenoliximab, TNX/355, TRX/1, IOT4a, priliximab, 4162W94, an anti-CD4 antibody comprising the six CDR sequences of anyone of the antibodies in said group； and (b) an antigen binding fragment of anyone of the antibodies of (a) wherein the antigen binding fragment comprises all six CDR sequences of anyone of said anti-CD4 antibodies from (a), and wherein the subject has received before the anti-CD4 antibody or antigen binding fragment thereof, or will receive simultaneously or separately with the anti-CD4 antibody or antigen binding fragment thereof, a psoralen compound, and wherein the subject (i) has received radiation； (ii) will be subjected to radiation； or (iii) has received radiation and will be subjected to further radiation.
